Effect of a hormone-releasing intrauterine system (Mirena®) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not, to endometrial resection by Maia, Hugo et al.
© 2012 Maia Jr et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Women’s Health 2012:4 175–183
International Journal of Women’s Health
Effect of a hormone-releasing intrauterine system 
(Mirena®) on aromatase and Cox-2 expression  
in patients with adenomyosis submitted  
or not, to endometrial resection
Hugo Maia Jr1,2
Clarice Haddad1
Julio Casoy1
Rebeca Maia1
Nathanael Pinheiro3
Elsimar M Coutinho1
1Centro de Pesquisa e Assistência 
em Reprodução Humana (CEPARH), 
2Itaigara Memorial Day Hospital, 
3IMAGEPAT, Salvador, Bahia, Brazil
Correspondence: Hugo Maia Jr 
CEPARH, Rua Caetano Moura,  
35, 40210-341 Salvador, Bahia, Brazil 
Tel +55 71 3247 8216 
Fax +55 71 3235 3442 
Email ceparh@uol.com.br
Objective: To investigate the effect of a levonorgestrel-releasing intrauterine system (Mirena®) 
on aromatase and cyclooxygenase-2 (Cox-2) expression in the endometrium of patients with 
adenomyosis who were submitted to endometrial resection at the time of insertion, compared 
to a group not submitted to endometrial resection and a group of controls with adenomyosis 
not submitted to any previous hormonal treatment.
Patients and methods: Patients with adenomyosis (n = 89) were included in this study. 
  Twenty-two patients had been using Mirena® for 5 years but had not been submitted to endometrial 
resection prior to insertion of the device. Twenty-four patients were submitted to endometrial 
resection at the time of Mirena® insertion. The remaining 43 patients with   adenomyosis had 
undergone no previous hormonal treatment and served as a control group. Cox-2 and aromatase 
expression were determined in the endometrium by immunohistochemistry.
Results: Use of Mirena® for 5 years reduced aromatase expression in the endometrium;   however, 
this reduction was significantly greater in the uteri previously submitted to endometrial resection. 
The reduction in Cox-2 expression was significant only in the uteri submitted to endometrial 
resection followed by the insertion of Mirena®.
Conclusion: Endometrial resection followed by the insertion of Mirena® was associated with 
greater rates of amenorrhea in patients with adenomyosis, which in turn were associated with a 
more effective inhibition of aromatase and Cox-2 expression in the endometrium.
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Introduction
Adenomyosis is a frequent cause of abnormal uterine bleeding and pain in women 
of reproductive age. Although hysterectomy has always been advocated as an 
  effective treatment, less invasive procedures such as endometrial resection have been 
  proposed as an alternative; however, these procedures may be associated with lower 
  success rates.
Nevertheless, the poor rates of amenorrhea may be due more to the intrinsic 
capacity of the endometrium to regenerate rather than to any fault in the actual 
technique.1 Several recent studies have shown the presence of aromatase expression 
in the endometrium of patients with adenomyosis, myomas, and endometrial polyps.2,3 
Locally produced estrogens upregulate several angiogenic and inflammatory factors 
in the endometrium, thus enabling this tissue to regenerate more effectively following 
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hysteroscopic surgery. This would explain the resumption 
of bleeding and the low rates of amenorrhea achieved with 
endometrial ablation. It is therefore important that aromatase 
expression be suppressed in order to achieve better rates 
of amenorrhea following endometrial resection. Several 
different progestins have been shown to inhibit aromatase, 
vascular endothelial growth factor, and cyclooxygenase-2 
(Cox-2) expression in the endometrium.2,4–6 This effect may 
help improve the surgical efficacy of endometrial resection 
for the treatment of menorrhagia by creating a long-lasting 
suppressive effect on the activity of these enzymes and growth 
factors in the endometrium. This can be achieved by inserting 
a levonorgestrel-releasing intrauterine system (Mirena®) 
immediately following endometrial resection. The insertion 
of Mirena® would also provide effective contraception for 
patients undergoing endometrial resection.
In the present study, the effect of Mirena® on aromatase 
and Cox-2 expression in the endometrium was evaluated 
in the fifth year of use of this device by patients previously 
submitted to endometrial resection at the time of insertion. 
These patients were compared with another group of women 
with adenomyosis in the fifth year of use of Mirena® who had 
not been submitted to endometrial ablation and to a control 
group of women who had undergone endometrial resection 
for adenomyosis but who had not been submitted to any 
hormonal treatment in the 3 months preceding the study.
Patients and methods
Patients (n = 89) aged 30–48 years with a history of 
menorrhagia and adenomyosis were included in this 
observational, case-control study. Enrolled patients 
had already completed their families and were seeking 
an alternative to hysterectomy. For the purpose of analysis, 
the patients included in the study were separated into 
three groups.
Group A consisted of 22 patients who had completed 
5 years of Mirena® use. The device was originally inserted 
in the women in this group as an outpatient procedure to treat 
excessive menstrual bleeding due to adenomyosis. In this 
group, hysteroscopy including an endomyometrial biopsy was 
carried out to establish the diagnosis of adenomyosis at the 
time of Mirena® insertion. The myometrial biopsy was carried 
out using a 5 mm forceps used in laparoscopy for ovarian 
biopsy, which was inserted through the cervix immediately 
prior to Mirena® insertion. The use of this forceps permits a 
sufficiently large fragment of the myometrium to be obtained 
to enable a histological diagnosis of adenomyosis to be 
made. Eighteen of the patients in this group were submitted 
to an endometrial resection at the time of insertion of the 
replacement device. The procedure was carried out using the 
bipolar resectoscope (Versapoint™ Gynecare, Ethicon, Inc, 
Somerville, NJ) under paracervical block, associated with 
intravenous propofol as previously described.6 In brief, the 
surgical technique consisted of dilating the cervix to 9 mm 
to allow the introduction of a bipolar resectoscope. A 0.9% 
solution of isotonic saline was used as the distention medium 
for the uterine cavity. The endometrium was removed during 
surgery together with approximately 5 mm of the underlying 
myometrium. This procedure was carried out in a private 
hospital setting and the patients were discharged 6 hours 
after its completion. In the remaining four patients in this 
group, a replacement Mirena® was inserted but endometrial 
ablation was not performed; however, an endomyometrial 
biopsy was taken at the time of the procedure to establish 
whether or not adenomyosis was present.
Group B consisted of 24 patients with histologically 
proven adenomyosis in whom Mirena® was inserted at the time 
of endometrial resection for the treatment of menorrhagia. 
All the women in this group had been using the device for 
at least 5 years when they returned to this center to have it 
replaced. Outpatient hysteroscopy was performed using a 
Bettocchi hysteroscope (Karl Storz, Tuttlingen, Germany) 
under paracervical block established with 10 mL of lidocaine 
1% prior to reinsertion of a replacement Mirena®. The 
previous device was easily removed and an endomyometrial 
biopsy was performed by inserting a 5-mm forceps into the 
uterus as described previously. A replacement Mirena® was 
then inserted without any difficulty.
Group C consisted of 43 patients submitted to endometrial 
resection between March 2009 and September 2011 in whom 
pathology revealed adenomyosis. Since they had not been 
submitted to any hormonal treatment for menorrhagia in the 
3 months preceding hysteroscopic surgery, these patients were 
included as untreated controls to determine the prevalence of 
aromatase and positive Cox-2 expression in the endometrium. 
This group was necessary because when Mirena® was 
inserted in groups A and B the pathology laboratory was not 
equipped to perform immunohistochemistry.
All surgical procedures were carried out by the same 
group of surgeons. Pathology and immunohistochemical 
analysis of the endometrium and myometrium were 
performed by the same pathologist.
Data on the menstrual-related symptoms such as 
menorrhagia, dysmenorrhea, and the premenstrual syndrome 
reported by these patients prior to treatment were obtained 
from their medical records.
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During hysteroscopy performed using the Versapoint™ 
resectoscope, the endometrium and approximately 0.5 cm 
of the myometrium were removed as described on 
previous page, fixed in 4% formalin, and sent to pathology 
for histological and immunohistochemical evaluation. 
Immunohistochemistry was performed following antigen 
retrieval to detect the presence of aromatase p450 and Cox-2 
expression. Aromatase expression was investigated using a 
commercially available monoclonal antibody, MCA2077, 
clone H4 (Serotech, Raleigh, NC), while Cox-2 expression 
was assessed using CX-294. Antigen retrieval was performed 
using the   Tris-EDTA buffer at pH 8.0. The reaction was 
revealed using the streptavidin-biotin method. The presence 
of aromatase expression was rated either as positive if 
there was any detectable staining reaction in the glandular 
epithelium or negative when no reaction was observed. 
Cox-2 expression was graded as 0 when no expression was 
detected, +1 when there was a light staining in more than 
10% of the glands, +2 when staining was moderate, and +3 
when there was strong expression in the endometrium. In 
all cases, slides were evaluated by a pathologist. Placental 
tissue and a sample of the atrophic endometrium were 
used as positive and negative controls, respectively, in all 
immunostaining reactions for aromatase p450. Statistical 
analysis was performed using the chi-square test to detect 
differences in percentages and Student’s t-test for comparison 
of means. Significance was established at P , 0.05. All 
patients gave their written informed consent authorizing 
the immunohistochemical studies to be performed on the 
endometrial tissue, as determined by the hospital’s internal 
review board. The insertion of Mirena® following endometrial 
resection has been the standard treatment for menorrhagia in 
this day hospital for a decade and all patients were adequately 
counseled prior to the procedure. A previous study conducted 
by our group had shown that endometrial resection without 
the concomitant use of Mirena® was associated with much 
lower amenorrhea rates than when this device was inserted 
at the time of surgery.6 For this reason, patients submitted to 
an endometrial resection for the treatment of adenomyosis-
related menorrhagia were always adequately counseled to 
have a Mirena® device inserted right after completion of the 
procedure.
Results
Histology and hysteroscopy findings
In the group of untreated patients with a histological 
diagnosis of adenomyosis, the endometrium was in the 
  proliferative phase in 28 cases and in the secretory phase 
in the remaining 15. On the other hand, in patients using 
Mirena®, the most common histological pattern reported 
consisted of an eutopic endometrium with atrophic glands in 
the presence of stroma with a decidual reaction or atrophic 
changes (Figure 1 and 2). These results are summarized 
in Table 1.
In eight patients of group B who had adenomyosis at 
the time of endometrial resection and Mirena® insertion, 
examination of the myometrium failed to detect the presence 
of ectopic endometrial tissue when the device was replaced 
5 years later.
The uterine cavity appeared normal at hysteroscopy in 
80% of the patients in the untreated control group; however, 
in 20% of cases an endometrial polyp was also detected.
In patients using Mirena® who had not previously been 
submitted to endometrial resection, the endometrium was 
thin; however, the presence of dilated blood vessels was 
detected, a finding that was not present in the group of 
women who had an endometrial resection at the time of 
insertion (Figure 3).
Menstrual symptoms in Mirena® users
The incidence of amenorrhea at the fifth year of use was 84% 
in the group of patients who had an endometrial resection 
at the time of Mirena® insertion and only 19% in the group 
not submitted to this procedure (P , 0.0001). Complete 
resolution of dysmenorrhea was reported by 91% of the 
patients who had undergone endometrial   resection followed 
by Mirena® insertion, while in the group not submitted to 
resection, only 20% of patients reported complete disappear-
ance of this symptom at the fifth year of use (P = 0.0005). 
The occurrence of dysmenorrhea was consistently associated 
with the presence of uterine bleeding.
Figure 1 Atrophic endometrium in a patient who had been using Mirena® for 5 years.
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Aromatase expression
The staining reaction for aromatase was detected using 
immunohistochemistry not only in the glandular epithelium 
of the eutopic endometrium but also in the ectopic 
glands embedded in the myometrium in the untreated 
controls with adenomyosis (Figure 4). In all cases there 
was agreement between the positive staining in both the 
eutopic and ectopic endometrium. In the untreated group, 
aromatase expression was present in 23/28 cases during the 
proliferative phase and in 9/15 cases in the luteal phase of 
the menstrual cycle, a difference that was not statistically 
significant (P = 0.2). For this reason, the results were 
Figure 2 Secretory endometrium in a patient with adenomyosis not previously treated with hormones. (A) Hysteroscopy; (B) Adenomyosis; (C) Secretory eutopic 
endometrium.
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pooled together and analyzed as a single group of untreated 
control patients (group C).
In contrast, in patients with adenomyosis using Mirena®, 
there were significantly fewer cases in which a positive 
staining reaction for aromatase could still be detected in both 
the eutopic endometrium and in the ectopic glands   embedded 
in the myometrium at the end of the fifth year of use when 
compared to the untreated patients with adenomyosis 
(group C) (Figure 5). Although this decrease in the number 
of cases was statistically significant in both group A and 
group B, it was significantly greater in the group previously 
submitted to an endometrial resection when compared to the 
group of women who had not undergone resection, being 
detected in only 1/24 of cases in the former. The difference 
between groups A and B was statistically significant 
(P , 0.01). These results are summarized in Table 2.
Cox-2 expression
The mean intensity of Cox-2 expression did not vary 
 significantly between the proliferative and luteal phases of the 
menstrual cycle in the untreated patients with adenomyosis, 
and for this reason the results were analyzed together 
(group C) (Figures 6 and 7). However, in the patients who 
had been using Mirena® for 5 years, a significant reduction 
occurred in the mean intensity of Cox-2 expression only in 
the group of patients who had been submitted to endome-
trial resection at the time of Mirena® insertion (group B) 
(Figure 8). Conversely, in patients not submitted to this 
procedure, the mean intensity scores for Cox-2 in the glan-
dular epithelium were not significantly different from those 
found in the untreated controls and significantly higher 
than those found in group B. These results are summarized 
in Table 3.
Discussion
The findings of the present study show that the use of Mirena® 
following endometrial resection in uteri with adenomyosis is 
associated with higher rates of amenorrhea and lower rates 
of dysmenorrhea compared to a group of women who had 
Mirena® inserted but who were not submitted to endometrial 
resection. Although this was not a prospective clinical trial 
designed specifically to address the question of whether endo-
metrial resection improves rates of amenorrhea in Mirena® 
users, the amenorrhea rates reported here are similar to those 
cited in the literature for patients with adenomyosis who 
had not been submitted to prior endometrial ablation.7 The 
presence of Mirena® inhibited the expression of aromatase 
and p450, thus exerting a local anti-estrogenic effect on 
the endometrium, which is beneficial in the treatment of 
adenomyosis. The suppression of aromatase in this tissue may 
explain the efficacy of Mirena® in halting the progression of 
endometriosis, since the seeding of aromatase-positive cells 
through retrograde menstruation may play an important role 
in the development of this disease.8
Figure  3  Presence  of  dilated  vessels  in  the  endometrium  of  a  patient  with 
adenomyosis who had been using a Mirena® device for 5 years.
Figure  4  Aromatase  expression  in  the  glandular  epithelium  of  a  patient  with 
adenomyosis during the proliferative phase.
Table  1  Endometrial  histology  in  patients  with  adenomyosis 
according to group
Group A  
(n)
Group B  
(n)
Group C 
(n)
Proliferative endometrium 0 0 28
Secretory endometrium 0 0 15
Atrophic glands + decidual stroma 16 15 0
Atrophic glands + atrophic stroma 6 9 0
Abbreviation: n, number of patients.
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Aromatase expression in the endometrium is activated by 
exposure to prostaglandin E2, thus establishing a link between 
inflammation and the development of this pathology.9 The 
greater Cox-2 expression in the endometrium of women 
using Mirena® who had not been submitted previously to 
ablation correlates positively with the occurrence of uterine 
bleeding, which is consistent with the role of prostaglandins 
and the ensuing inflammation in the pathogenesis of both 
menorrhagia and breakthrough bleeding during the use of 
oral contraceptives and the progestin-only pill.10–12
The rate of amenorrhea reported here during the fifth year 
of Mirena® use also compares favorably with rates reported 
previously by our group 1 year after insertion of this device.6 
These rates are also far superior to those achieved with the 
insertion of Mirena® alone in patients with adenomyosis, 
myomas, or menorrhagia.13–15
The presence of adenomyosis specimens removed 
at hysterectomy from patients with persistent bleeding 
following the insertion of Mirena® or microwave endometrial 
ablation16–19 is noteworthy and suggests that the presence of 
Figure 5 Positive aromatase expression in the eutopic endometrium of a patient with adenomyosis (A) and negative expression in a patient after using a Mirena® device for 
5 years (B).
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adenomyosis increases the risk of failure of both forms of 
treatment due to the resumption of menorrhagia, probably 
caused by persistent Cox-2 activation and the less effective 
inhibition of aromatase in patients not submitted to 
endometrial resection. Another factor which may contribute 
to the high incidence of amenorrhea in patients using 
Mirena® after endometrial resection would be the direct 
exposure of the ectopic glands in the myometrium to levels 
of levonorgestrel higher than those achieved when the 
endometrium is intact. This would lead to a more effective 
inhibition of both aromatase and Cox-2 in the ectopic glands 
deeply embedded in the myometrium, resulting in better 
rates of amenorrhea. This is in agreement with the findings 
of a previous study showing that the levonorgestrel levels in 
the endometrium of patients using Mirena® are many times 
higher than levels in the myometrium, which are similar to 
those found in extrauterine tissue.20 This suggests that the 
intact endometrium may act as a barrier, preventing the 
diffusion of levonorgestrel to the underlying myometrium, 
which receives levonorgestrel only through the systemic 
circulation. This may explain why the rates of amenorrhea 
in the present study were far higher in the group of women 
with adenomyosis submitted to endometrial resection 
compared to those using Mirena® alone. In the latter, because 
the endometrium remains intact, the levonorgestrel levels 
in the myometrium may not be high enough to effectively 
suppress both aromatase and Cox-2 expression in the 
deeply embedded ectopic glands. This would explain the 
increased efficacy of Mirena® in inhibiting these enzymes in 
uteri with adenomyosis when the endometrium is removed 
prior to insertion of the device. Although this was not a 
subject of the present study, it is likely that endometrial 
resection may improve the diffusion of levonorgestrel into 
the myometrium; however, for the present moment this 
hypothesis has to be considered speculative. This may also 
explain the reduction in breakthrough or irregular bleeding 
with this combined method compared to rates reported in the 
literature when Mirena® is used without prior endometrial 
resection in patients with adenomyosis or myomas.21 
The decrease in aromatase expression in adenomyosis 
uteri bearing a Mirena® device seems to occur even when 
Cox-2 expression is not suppressed by the treatment. Since 
prostaglandins are an important inductor for the activation 
of the aromatase gene in the endometrium, a direct effect 
of the progestin inhibiting gene transcription would be the 
likely mechanism.8,9,11
The combination of Mirena® with endometrial resection 
represents a viable and effective alternative therapy to 
hysterectomy for the management of menorrhagia and 
dysmenorrhea in patients with adenomyosis and menorrhagia. 
In patients undergoing endometrial resection alone or Mirena® 
insertion alone for the treatment of menorrhagia, it is important 
to remember that success rates are lower than when both 
methods are used together. This has been shown in a previous 
study conducted by our group to compare the amenorrhea and 
success rates of the combination of Mirena® and endometrial 
resection versus endometrial resection alone for the treatment 
of adenomyosis-related menorrhagia.6 Similar results were also 
reported more recently by another group.22
In conclusion, Mirena® is an effective option for the 
suppression of aromatase and Cox-2 expression in the 
endometrium of patients with adenomyosis; however, 
inhibition appears to be greater when this device is inserted 
immediately following endometrial resection. Nevertheless, 
it should be noted that endometrial resection is an alterna-
tive to hysterectomy and is not an option for women who 
still want to preserve their fertility. In this case, particularly 
when used to treat adenomyosis-related menorrhagia, the 
insertion of Mirena® alone is a viable option, since fertility 
returns promptly after removal of the device.23
Table  2 The  effect  of  Mirena®  and  endometrial  resection  on 
aromatase expression in the glandular epithelium of adenomyosis 
lesions
Group Positive 
endometrium
Group A: Mirena® alone 8/22 36%
Group B: Mirena® after endometrial resection 1/24 4%
Group C: untreated adenomyosis 32/43 74%
Notes: Chi-square test: difference between groups A and B: P , 0.01; difference 
between groups A and C: P = 0.02; difference between groups B and C: P , 0.0001.
Figure  6  Cox-2  expression  in  a  patient  with  adenomyosis  during  the  pro  li  fer-
ative phase.
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Figure 7 Immunohistochemical grading of Cox-2 expression in the eutopic endometrium of patients with adenomyosis. (A) 1+ expression and (B) 3+ expression.
Figure 8 Cox-2 negative expression in a patient using Mirena® who had been previously submitted to an endometrial resection.
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Because of the negative impact on quality of life caused 
by the pain and excessive bleeding associated with adeno-
myosis, hysterectomy remains the standard treatment for this 
pathology.24 Development of alternative methods of treatment 
capable of offering effective relief of these symptoms without 
constituting a major surgical procedure would be desirable. In 
this aspect, the combination of Mirena® with endometrial resec-
tion fulfills these requisites, since it is a less invasive procedure 
compared to hysterectomy and its success rate is high. However, 
further prospective studies must be conducted before changes 
in standard medical practice can be contemplated.
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Table 3 Mean Cox-2 expression in the endometrium of patients 
with adenomyosis in use of Mirena®
Group Mean Cox-2 
expression
Group A: Mirena® alone 1.6 ± 0.9 (n = 22)
Group B: Mirena® after endometrial resection 0.7 ± 1 (n = 24)
Group C: untreated adenomyosis 1.7 ± 0.7 (n = 43)
Notes: Student’s t-test: difference between groups A and B: P , 0.0001; difference 
between groups A and C: P = 0.02; difference between groups B and C: P , 0.0001.
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